Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A

Meetings and Events

Grand Rounds

Upcoming CME Conferences


Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue.

Submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Advanced Genomic Profiling Now Available

The clinical impact of the new Cedars-Sinai Comprehensive Cancer Gene panel is broad and will allow Cedars-Sinai to compete with academic medical centers and large reference laboratories to offer the best possible diagnostic testing.

"We developed our Cedars-Sinai Comprehensive Cancer Gene panel in alignment with the National Cancer Institute to assure that we can detect every possible DNA mutation and genomic alteration that has an FDA-approved therapy, an 'off label' drug treatment, or clinical trial eligibility," said Eric Vail, MD, director of Molecular Pathology in the Department of Pathology and Laboratory Medicine. "Coupled with a quick turnaround time, measured in days instead of weeks, we can profile hundreds to thousands of patients each year."

Additionally, the panel can be easily ordered in CS-Link™ with the genomic findings interpreted in the context of the patient's other lab results and clinical information, which reference labs simply cannot do.

Cedars-Sinai’s next-generation sequencing capabilities now report point mutations, insertions, deletions, translocations, copy number variations, tumor mutational burden and microsatellite instability.

"Comprehensive interpretation is provided by our expert molecular genetic pathologists for every case, and on-site consultation is readily available," said Vail. "With these capabilities patients will be opened up to options like immunotherapy and clinical trials that may have been limited before."